About Nightstar
Nightstar is a Healthcare company based in London (United Kingdom) founded in 2013, and was acquired by Biogen in March 2019. Gene therapies for inherited retinal diseases are developed. Nightstar has raised $99.88 million across 3 funding rounds from investors including Biogen, Syncona and Imperial Innovations. The company has 15 employees. Its chief executive, as recorded, is Dave Fellows. Nightstar offers products and services including Alzheimer's Therapies, Multiple Sclerosis Medicines, and Spinal Muscular Atrophy Treatments. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is NIGHTSTARX LIMITED.
Company details
Nightstar was founded in 2013 in London, United Kingdom, within the biotechnology sector focused on gene therapy. Retinal disorders are addressed through candidates such as NSR-REP1, designated as an orphan drug by the FDA and EMA for choroideremia, NSR-RPGR in Phase 12 trials for X-linked retinitis pigmentosa, and NSR-BEST1 under preclinical evaluation for Best vitelliform macular dystrophy. Operations center on advancing these therapies for rare genetic conditions.
- Headquarters London, United Kingdom
- Employees 15
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website nightstartx.com
- Social LinkedIn
- Acquired by Biogen (Mar 2019)
- Legal Name Nightstarx Limited
- Date of Incorporation 31 May, 2013
- Jurisdiction MAIDENHEAD, BERKSHIRE, ENGLAND
Products & Services of Nightstar
Nightstar offers a comprehensive portfolio of products and services, including Alzheimer's Therapies, Multiple Sclerosis Medicines, and Spinal Muscular Atrophy Treatments.
Treatments targeting neurological disorders like Alzheimer's.
Therapies for managing multiple sclerosis symptoms.
Medications for rare genetic disorders affecting muscles.
Funding Insights of Nightstar
Nightstar has successfully raised a total of $99.88M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $45 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $99.88M
- Total Rounds 3
- Last Round Series C — $45M
- First Round $19.88M
(Jan 2014)
- Investors Count 5
All 3 funding rounds of Nightstar with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2017 | $45M | Series C | – | – | |
| Nov 2015 | $35M | Series B | – | New Enterprise Associates | – |
| Jan 2014 | $19.88M | Series A | – | – |
6 investors in total: 6 institutional.
Investors in Nightstar
Nightstar has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Biogen, Syncona and Imperial Innovations.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare investments are managed via private equity by Syncona. | 2012 | synconaltd.com | London, United Kingdom | |
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Investments in startups are focused on Europe and the US. | 1986 | imperialinnovations.co.uk | London, United Kingdom | |
Diversified investment management services are provided to institutional clients. | wellington.com | Boston, United States | ||
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
Therapies for neurodegenerative and immunology disorders are developed. | 1978 | biogen.com | Cambridge, United States |
Investor details for Nightstar
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nightstar
1 people are tracked at Nightstar (1 in leadership); the tracked headcount is 15.
| Name | Role | Group |
|---|---|---|
Dave Fellows | CEO | Leadership |
Complete people profiles for Nightstar
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Nightstar
5 dated milestones of Nightstar across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Nightstar is founded.
- Funding First funding round of $19.9M.
- Funding Latest funding round, Series C, of $45.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Biogen.
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as Nightstar (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nightstar
Complete news archive for Nightstar
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nightstar
Nightstar was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Nightstar is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Dave Fellows is the CEO of Nightstar, as recorded in our data.
Nightstar is a funded company, having raised a total of $99.88M across 3 funding rounds to date. The company's 1st funding round was a Series A of $19.88M, raised on Jan 2014.
Nightstar has 15 employees.
Nightstar was founded in 2013 in London, United Kingdom, within the biotechnology sector focused on gene therapy. Retinal disorders are addressed through candidates such as NSR-REP1, designated as an orphan drug by the FDA and EMA for choroideremia, NSR-RPGR in Phase 12 trials for X-linked retinitis pigmentosa, and NSR-BEST1 under preclinical evaluation for Best vitelliform macular dystrophy. Operations center on advancing these therapies for rare genetic conditions.
Nightstar offers Alzheimer's Therapies, Multiple Sclerosis Medicines, and Spinal Muscular Atrophy Treatments.
Nightstar has 6 investors. Key investors include Biogen, Syncona, Imperial Innovations, Wellington, and NEA.
Nightstar operates through Nightstarx Limited.
Yes. Nightstar was acquired by Biogen in March 2019.